Peer-Reviewed Article December 31, 2008
TRIPLE-NEGATIVE BREAST CANCER
Are you an author of this work?Link to your sovereign AfriScholar profile
Published in: Research in Oncology
Publisher: Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine • Egypt • 2357-0687 • 2357-0695
Abstract
Breast cancers are represented by a heterogeneous group of tumors, characterized by a wide spectrum of clinical, pathologic and molecular features 1-3 .This wide spectrum of factors accounts for variations in response to therapy and outcomes among women diagnosed with breast cancer 4-6 .Steroid hormone receptors (HR) such as estrogen receptor (ER) and progesterone receptor (PgR) in concert with the oncogene ErbB-2/human epidermal growth factor receptor 2 (HER-2) are critical determinants of these BC subtypes.While HR are thought to mirror a good prognosis, expression of HER-2 has long been understood as an unfavorable prognostic feature 7,8 .